Reston, VA (September 25, 2026)— New research has been published ahead-of-print by The Journal of Nuclear Medicine ( JNM ). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Molecular Imaging Tracks Inflammation and Fibrosis in Liver Injury
In a mouse model of liver fibrosis, several PET tracers were evaluated across inflammation, fibrosis, and regression. FDG uptake increased during early disease, while a CXCR4-targeted tracer identified inflammation and an αvβ6-integrin tracer reflected fibrotic activity. Two FAP tracers showed unexpectedly reduced uptake despite evidence of FAP-positive cells.
Radioactive Iodine Treatment Shows Similar Results With Two Thyroid Preparation Methods
In patients with differentiated thyroid cancer and distant metastases, radioactive iodine therapy prepared with recombinant human thyrotropin or thyroid hormone withdrawal (THW) was associated with similar overall and disease-specific survival and comparable imaging and biochemical responses. Laboratory-based safety abnormalities, including liver function changes, occurred more often after THW.
Targeted Radiation Delivery Shows Potential for Treating Liver Metastases
A small prospective trial evaluated a personalized approach to delivering 177 Lu-DOTATATE to patients with liver-dominant metastatic neuroendocrine tumors. Administering the treatment directly through the hepatic arteries increased radiation delivery to liver metastases compared with intravenous administration, while the four-cycle treatment was generally well tolerated and produced tumor responses in most patients.
Genetic Changes May Help Predict Response to Prostate Cancer Radiopharmaceutical Therapy
In 205 patients with metastatic castration-resistant prostate cancer treated with 177 Lu-PSMA-617, outcomes varied according to specific genetic alterations. Patients with ATM alterations had greater PSA reductions and longer progression-free and overall survival, while CDK12 alterations were associated with shorter survival. Findings highlight differences among individual genes involved in DNA repair.
New PSMA-Targeted Therapy Shows Favorable Safety Profile in Prostate Cancer
A phase 1 study evaluated escalating doses of the investigational radiopharmaceutical 177 Lu-P17-087 in nine patients with metastatic castration-resistant prostate cancer. The treatment cleared rapidly from the blood while remaining in tumor lesions, resulting in low radiation doses to the kidneys and bone marrow. Most patients experienced a decline in PSA levels.
New Radiopharmaceutical Shows Promise for Treating Neuroendocrine Tumors
A phase 1 study evaluated 177 Lu-DOTA-EB-TATE, an investigational treatment designed to remain in the bloodstream longer and increase radiation delivery to neuroendocrine tumors. In six patients with advanced gastroenteropancreatic tumors, treatment was generally well tolerated, with no kidney toxicity observed. Most patients had stable disease at three months, while one had a partial response.
Kidney Function Remains Stable During 177 Lu-PSMA-617 Treatment for Prostate Cancer
A study compared kidney function in patients with metastatic castration-resistant prostate cancer receiving 177 Lu-PSMA-617 or chemotherapy. After adjustment for risk factors, early kidney function changes were similar between treatments. Over longer follow-up, kidney function declined in some patients, particularly those with chronic kidney disease before treatment.
Visit the JNM website for the latest research, follow our Twitter and Facebook pages @JournalofNucMed, and join us on LinkedIn .
###
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or rmaxey@snmmi.org .
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 90 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org .
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org .
Journal of Nuclear Medicine